Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic lupus erythematosus

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Biajoux, Vincent ^a,b   Bignon, Alexandre ^a,b   Freitas, Christelle ^a,b   Martinez, Valérie ^a,b,c   Thelen, Marcus ^d   Lima, Guadalupe ^e   Jakez Ocampo, Juan ^e   Emilie, Dominique ^a,b,c   Llorente, Luis ^e   Balabanian, Karl ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSERM   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Autoimmunity; B cells; Chemokines; CXCR4; CXCR7; Migration; Systemic Lupus Erythematosus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CD19 ANTIGEN; CD27 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STROMAL CELL DERIVED FACTOR 1;

ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CHEMOTAXIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOSOL; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HISPANIC; HUMAN; HUMAN CELL; KRUSKAL WALLIS TEST; LEUKOCYTE; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANK SUM TEST; RECEPTOR DOWN REGULATION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; B-LYMPHOCYTES; CELL COUNT; CELL MEMBRANE; CHEMOKINE CXCL12; CHEMOTAXIS; DEMOGRAPHY; ETHNIC GROUPS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SPACE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEXICO; MIDDLE AGED; PLASMA CELLS; RECEPTORS, CXCR; RECEPTORS, CXCR4; YOUNG ADULT;

EID: 84871172859     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-251     Document Type: Article

References (64)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939. 10.1056/NEJMra071297, 18305268.
2. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 2010, 6:683-692. 10.1038/nrrheum.2010.176, 3135416, 21060334.
3. Mitchison NA, Wedderburn LR. B cells in autoimmunity. Proc Natl Acad Sci USA 2000, 97:8750-8751. 10.1073/pnas.97.16.8750, 34006, 10922029.
4. Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol 2010, 42:543-550. 10.1016/j.biocel.2009.10.011, 2835836, 19850148.
5. Deshmukh US, Bagavant H, Fu SM. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev 2006, 5:414-418. 10.1016/j.autrev.2005.10.010, 16890896.
6. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342. 10.1002/art.10949, 12746906.
7. Pisetsky DS, Grammer AC, Ning TC, Lipsky PE. Are autoantibodies the targets of B-cell-directed therapy?. Nat Rev Rheumatol 2011, 7:551-556. 10.1038/nrrheum.2011.108, 21808289.
8. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieva JA. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther 2010, 12:R108. 10.1186/ar3042, 2911899, 20525218.
9. Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM, Hansen A, Hostmann A, Frolich D, Dorner T. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R204. 10.1186/ar3179, 3046510, 21050432.
10. Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nat Immunol 2008, 9:953-959. 10.1038/ni.f.207, 18711432.
11. Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011, 2011:432595. 3196871, 22028588.
12. Ezzat M, El-Gammasy T, Shaheen K, Shokr E. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement. Lupus 2011, 20:845-854. 10.1177/0961203311398513, 21576203.
13. Chong BF, Mohan C. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 2009, 13:1147-1153. 10.1517/14728220903196761, 19670960.
14. Ansel KM, Cyster JG. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol 2001, 13:172-179. 10.1016/S0952-7915(00)00201-6, 11228410.
15. Palmesino E, Moepps B, Gierschik P, Thelen M. Differences in CXCR4-mediated signaling in B cells. Immunobiology 2006, 211:377-389. 10.1016/j.imbio.2005.12.003, 16716807.
16. Wang A, Guilpain P, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ, Lin F, Fairhurst AM, Boudreaux C, et al. Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum 2010, 62:3436-3446. 10.1002/art.27685, 20722038.
17. Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, Baleux F, Portier A, Durand-Gasselin I, Coffman RL, et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003, 170:3392-3400.
18. Lugar PL, Love C, Grammer AC, Dave SS, Lipsky PE. Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. PLoS One 2012, 7:e44362. 10.1371/journal.pone.0044362, 3448624, 23028528.
19. Thelen M, Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio?. J Neuroimmunol 2008, 198:9-13. 10.1016/j.jneuroim.2008.04.020, 18533280.
20. Ulvmar MH, Hub E, Rot A. Atypical chemokine receptors. Exp Cell Res 2011, 317:556-568. 10.1016/j.yexcr.2011.01.012, 3072526, 21272574.
21. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, Rot A, Thelen M. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 2010, 5:e9175. 10.1371/journal.pone.0009175, 2820091, 20161793.
22. Wang H, Beaty N, Chen S, Qi CF, Masiuk M, Shin DM, Morse HC. The CXCR7 chemokine receptor promotes B-cell retention in the splenic marginal zone and serves as a sink for CXCL12. Blood 2011, 119:465-468. 3257011, 22110250.
23. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 2010, 29:4599-4610. 10.1038/onc.2010.212, 3164491, 20531309.
24. Hoffmann F, Muller W, Schutz D, Schulz S, Stumm R. The CXCR7 C-terminal domain mediates efficient CXCL12 uptake and degradation. J Biol Chem 2012, 287:28362-28377. 10.1074/jbc.M111.335679, 22736769.
25. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci USA 2010, 107:628-632. 10.1073/pnas.0912852107, 2818968, 20018651.
26. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093. 10.1182/blood-2008-12-196618, 19380869.
27. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 Heterodimer Constitutively Recruits {beta}-Arrestin to Enhance Cell Migration. J Biol Chem 2011, 286:32188-32197. 10.1074/jbc.M111.277038, 3173186, 21730065.
28. Canals M, Scholten DJ, de Munnik S, Han MK, Smit MJ, Leurs R. Ubiquitination of CXCR7 controls receptor trafficking. PLoS One 2012, 7:e34192. 10.1371/journal.pone.0034192, 3311620, 22457824.
29. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005, 280:35760-35766. 10.1074/jbc.M508234200, 16107333.
30. Infantino S, Moepps B, Thelen M. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J Immunol 2006, 176:2197-2207.
31. Berahovich RD, Zabel BA, Penfold ME, Lewen S, Wang Y, Miao Z, Gan L, Pereda J, Dias J, Slukvin II, et al. CXCR7 protein is not expressed on human or mouse leukocytes. J Immunol 2010, 185:5130-5139. 10.4049/jimmunol.1001660, 20889540.
32. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, Dorner T. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008, 58:1762-1773. 10.1002/art.23498, 18512812.
33. Humpert ML, Tzouros M, Thelen S, Bignon A, Levoye A, Arenzana-Seisdedos F, Balabanian K, Bachelerie F, Langen H, Thelen M. Complementary methods provide evidence for the expression of CXCR7 on human B cells. Proteomics 2012, 12:1938-1948. 10.1002/pmic.201100581, 22623068.
34. Juarez-Cedillo T, Zuniga J, Acuna-Alonzo V, Perez-Hernandez N, Rodriguez-Perez JM, Barquera R, Gallardo GJ, Sanchez-Arenas R, Garcia-Pena Mdel C, Granados J, Vargas-Alarcon G. Genetic admixture and diversity estimations in the Mexican Mestizo population from Mexico City using 15 STR polymorphic markers. Forensic Sci Int Genet 2008, 2:e37-e39. 10.1016/j.fsigen.2007.08.017, 19083813.
35. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
36. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. a disease activity index for lupus patients. the committee on prognosis studies in SLE. Arthritis Rheum 1992, 35:630-640. 10.1002/art.1780350606, 1599520.
37. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, et al. The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011, 50:982-988.
38. Nieto JC, Canto E, Zamora C, Ortiz MA, Juarez C, Vidal S. Selective loss of chemokine receptor expression on leukocytes after cell isolation. PLoS One 2012, 7:e31297. 10.1371/journal.pone.0031297, 3293867, 22403612.
39. Balabanian K, Levoye A, Klemm L, Lagane B, Hermine O, Harriague J, Baleux F, Arenzana-Seisdedos F, Bachelerie F. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest 2008, 118:1074-1084. 2242619, 18274673.
40. Cikos S, Bukovska A, Koppel J. Relative quantification of mRNA: comparison of methods currently used for real-time PCR data analysis. BMC Mol Biol 2007, 8:113. 10.1186/1471-2199-8-113, 2235892, 18093344.
41. Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2005, 7:R1001-R1013. 10.1186/ar1776, 1257429, 16207316.
42. Payne D, Drinkwater S, Baretto R, Duddridge M, Browning MJ. Expression of chemokine receptors CXCR4, CXCR5 and CCR7 on B and T lymphocytes from patients with primary antibody deficiency. Clin Exp Immunol 2009, 156:254-262. 10.1111/j.1365-2249.2009.03889.x, 2759473, 19250276.
43. Jin Z, Nagakubo D, Shirakawa AK, Nakayama T, Shigeta A, Hieshima K, Yamada Y, Yoshie O. CXCR7 is inducible by HTLV-1 Tax and promotes growth and survival of HTLV-1-infected T cells. Int J Cancer 2009, 125:2229-2235. 10.1002/ijc.24612, 19623653.
44. Kumar A, Kremer KN, Dominguez D, Tadi M, Hedin KE. Galpha13 and Rho mediate endosomal trafficking of CXCR4 into Rab11+ vesicles upon stromal cell-derived factor-1 stimulation. J Immunol 2011, 186:951-958. 10.4049/jimmunol.1002019, 3057048, 21148034.
45. Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, Lebbe C, Kerob D, Dupuy A, Hermine O, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005, 105:2449-2457. 10.1182/blood-2004-06-2289, 15536153.
46. Cruz-Orengo L, Holman DW, Dorsey D, Zhou L, Zhang P, Wright M, McCandless EE, Patel JR, Luker GD, Littman DR, et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J Exp Med 2011, 208:327-339. 10.1084/jem.20102010, 3039853, 21300915.
47. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008, 84:1130-1140. 10.1189/jlb.0208088, 18653785.
48. Rettig MP, Ramirez P, Nervi B, DiPersio JF. CXCR4 and mobilization of hematopoietic precursors. Methods Enzymol 2009, 460:57-90.
49. Bleul CC, Schultze JL, Springer TA. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med 1998, 187:753-762. 10.1084/jem.187.5.753, 2212170, 9480985.
50. Wang A, Fairhurst AM, Tus K, Subramanian S, Liu Y, Lin F, Igarashi P, Zhou XJ, Batteux F, Wong D, et al. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol 2009, 182:4448-4458. 10.4049/jimmunol.0801920, 2946082, 19299746.
51. Maecker HT, McCoy JP, Amos M, Elliott J, Gaigalas A, Wang L, Aranda R, Banchereau J, Boshoff C, Braun J, et al. A model for harmonizing flow cytometry in clinical trials. Nat Immunol 2010, 11:975-978. 10.1038/ni1110-975, 3400260, 20959798.
52. Faint JM, Tuncer C, Garg A, Adams DH, Lalor PF. Functional consequences of human lymphocyte cryopreservation: implications for subsequent interactions of cells with endothelium. J Immunother 2011, 34:588-596. 10.1097/CJI.0b013e31822bc3d0, 21904217.
53. Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA, Massarotti E, Lu B, Solomon DH, Winkelmayer WC. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011, 63:1681-1688. 10.1002/art.30293, 3106117, 21445962.
54. Uribe AG, Romero-Diaz J, Apte M, Fernandez M, Burgos PI, Reveille JD, Sanchez-Guerrero J, Alarcon GS. Impact of immigration on the clinical expression of systemic lupus erythematosus: a comparative study of Hispanic patients residing in the USA and Mexico. Rheumatology (Oxford) 2009, 48:1392-1397.
55. Annunziato F, Cosmi L, Galli G, Beltrame C, Romagnani P, Manetti R, Romagnani S, Maggi E. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999, 65:691-699.
56. Postal M, Appenzeller S. The role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011, 56:537-543. 10.1016/j.cyto.2011.08.026, 21907587.
57. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
58. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175. 10.1038/ni1552, 18157131.
59. Robak E, Kulczycka L, Sysa-Jedrzejowska A, Wierzbowska A, Robak T. Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 2007, 18:181-187.
60. Sanchez-Alcaniz JA, Haege S, Mueller W, Pla R, Mackay F, Schulz S, Lopez-Bendito G, Stumm R, Marin O. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 2011, 69:77-90. 10.1016/j.neuron.2010.12.006, 21220100.
61. Winkelmann R, Sandrock L, Porstner M, Roth E, Mathews M, Hobeika E, Reth M, Kahn ML, Schuh W, Jack HM. B cell homeostasis and plasma cell homing controlled by Kruppel-like factor 2. Proc Natl Acad Sci USA 2011, 108:710-715. 10.1073/pnas.1012858108, 3021026, 21187409.
62. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, Woehl B, Leung H, Groom J, Batten M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA 2007, 104:14759-14764. 10.1073/pnas.0702229104, 1976222, 17804806.
63. Haege S, Einer C, Thiele S, Mueller W, Nietzsche S, Lupp A, Mackay F, Schulz S, Stumm R. CXC Chemokine receptor 7 (CXCR7) regulates CXCR4 protein expression and capillary tuft development in mouse kidney. PLoS One 2012, 7:e42814. 10.1371/journal.pone.0042814, 3412803, 22880115.
64. Odemis V, Boosmann K, Heinen A, Kury P, Engele J. CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. J Cell Sci 2010, 123:1081-1088. 10.1242/jcs.062810, 20197403.